Seeking Alpha

Novartis in talks to buy stem-cell firm for up to $600M

  • Novartis (NVS) is in advanced negotiations to acquire Israeli stem-cell treatments developer Gamida-Cell for up to $600M, Israel's Globes reports.
  • Novartis would pay hundreds of millions of dollars up front and the rest in milestones for the company, which develops therapies for a variety of conditions, including blood cancers and solid tumors.
  • Gamida shareholders Elbit Medical and Clal Biotechnology confirmed that a sizable offer had been made, but didn't disclose the suitor. Another investor is Teva (TEVA).
  • While talks are advanced, Gamida hasn't ruled out the prospect of an IPO in New York instead, although the firm's valuation in a listing would be lower.
Comments (1)
  • mikebrom
    , contributor
    Comments (25) | Send Message
    18 Mar 2014, 12:56 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs